Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. filed a Form S-3 automatic shelf registration statement that allows it to offer, from time to time after effectiveness, a mix of debt securities, common stock, preferred stock, depositary shares, warrants and units. Specific terms and amounts for each issuance will be set in later prospectus supplements.
The company, a gene therapy-focused life sciences business with programs including SGT-003 for Duchenne muscular dystrophy and other rare cardiac and neuromuscular conditions, states that net proceeds from any offerings are expected to be used for general corporate purposes, including R&D, clinical development, strategic transactions, debt repayment, working capital and capital expenditures.
The filing also details the general terms of potential senior and subordinated debt, capital stock (including “blank check” preferred stock), depositary shares, warrants, and units, as well as registration rights held by certain investors and anti-takeover provisions under Delaware law and the company’s governing documents.
Solid Biosciences Inc. reported a larger net loss as it advanced its neuromuscular and cardiac gene therapy programs in the quarter ended June 30, 2026. Net loss was $54.8 million for the quarter and $111.5 million for the first half, primarily reflecting higher research and development spending.
Research and development expenses rose to $44.3 million in the quarter and $90.4 million year-to-date, driven by SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT. General and administrative expenses were $13.1 million for the quarter and $24.3 million for six months.
Cash, cash equivalents and available-for-sale securities totaled $377.7 million as of June 30, 2026, supported by a March 2026 private placement and at-the-market stock sales. The company states it believes this liquidity will fund operating and capital needs into mid-2028.
FMR LLC and Abigail P. Johnson report beneficial ownership of Solid Biosciences Inc. common stock on a Schedule 13G. As of June 30, 2026, they beneficially owned 6,875,956.68 shares of common stock, representing 7.0% of the class.
FMR LLC reports sole voting power over 6,875,423 shares and sole dispositive power over 6,875,956.68 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 6,875,956.68 shares and no voting power, reflecting her control position over FMR entities.
The filing notes that one or more other persons have rights to receive dividends or sale proceeds from these shares, but no single such person has an interest exceeding five percent of Solid Biosciences’ outstanding common stock. The securities were acquired and are reported through subsidiaries identified in an attached Exhibit 99.
BlackRock, Inc. reports beneficial ownership of common stock of Solid Biosciences Inc. on a Schedule 13G filing. BlackRock reports beneficial ownership of 6,419,730 shares of Solid Biosciences common stock, representing 6.5% of the outstanding class.
BlackRock has sole voting power over 6,328,941 shares and sole dispositive power over 6,419,730 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends and sale proceeds, but no single underlying person holds more than five percent of the total outstanding common shares.
Solid Biosciences Inc. director Ian F. Smith increased his equity stake through equity compensation vesting. On July 2, 2026, he exercised restricted stock units to acquire 3,440 shares of Common Stock at a price of $0.00 per share, reflecting a conversion of vested awards rather than an open-market purchase.
The filing shows his direct holdings rose to 138,145 shares of Common Stock after the transaction, and he also holds 6,880 Restricted Stock Units. Footnotes state that restricted stock units convert to common stock on a one-for-one basis and were granted on January 2, 2026, vesting in equal quarterly installments over 12 months.
Solid Biosciences Inc. received an initial ownership report on Form 3 from RA Capital–affiliated entities as ten percent owners. The filing lists indirect holdings of 28,569, 109,661, and 11,897,896 shares of Common Stock held through investment vehicles managed by RA Capital Management, L.P.
The report also shows 8,178,412 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.001 per share. These warrants are exercisable immediately but subject to a 9.99% beneficial ownership limit that caps how many shares the Fund may hold after exercise.
RA Capital Management and affiliates report an updated stake in Solid Biosciences Inc., now beneficially owning 12,036,126 shares of common stock, or 11.9% of the company. Most of this is held through RA Capital Healthcare Fund, which directly owns 11,897,896 shares.
The position also includes pre-funded warrants exercisable for up to 8,178,412 additional shares, but a Beneficial Ownership Blocker prevents exercises that would lift the Fund’s holdings above 9.99% of Solid’s outstanding common stock. RA Capital serves as investment adviser to all reporting vehicles, while Kolchinsky and Shah are managers of RA Capital.
On June 18, 2026, the Fund bought 338,100 shares in open-market trades at prices between $8.25 and $8.35, with a weighted-average of $8.30 per share. On June 22, 2026, it purchased an additional 2,358,048 shares at $8.20 per share in an at-the-market offering by Solid Biosciences, all funded from the Fund’s working capital. Ownership percentages are calculated using 98,449,606 shares outstanding as of May 8, 2026, plus the 2,358,048 new ATM shares issued to the Fund.
Solid Biosciences Inc. reported that director Nagendran Sukumar received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.
The grant vests in full on the earlier of the one-year anniversary of June 10, 2026 or immediately before the company’s next annual stockholder meeting after that date. Any remaining unvested portion will also vest automatically upon specified change in control events, aligning the director’s compensation with company performance and potential strategic transactions.
Solid Biosciences director Ian F. Smith received a grant of stock options covering 77,500 shares of common stock. The Director Stock Option has an exercise price of $6.61 per share and, after this grant, Smith holds options on 77,500 shares directly.
The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant date. Any remaining unvested portion will also vest automatically upon specified change in control events. The option expires on June 10, 2036.
Solid Biosciences Inc. director Ilan Ganot received a new stock option grant. The Form 4 reports an award of 77,500 Director Stock Options, each exercisable for one share of common stock at an exercise price of $6.61 per share.
The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholders’ meeting after the grant. Any remaining unvested portion will also vest automatically upon specified change in control events. Following this award, Ganot directly holds options for 77,500 underlying shares.